Baird upgraded Tandem Diabetes (TNDM) to Outperform from Neutral with a price target of $30, up from $18. The firm adjusted ratings and medical technology as part of its 2026 outlook. Baird cites solid end markets, the company’s pharmacy revenue and margin tailwinds, and the Mobi-T mid-year launch for the upgrade of Tandem.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TNDM:
- Citi ups Tandem target, adds ‘downside 90-day catalyst watch’
- Tandem Diabetes price target raised to $23 from $17 at Morgan Stanley
- Tandem Diabetes Care Appoints Sandra Beaver to Board
- Tandem Diabetes price target raised to $17 from $13 at Morgan Stanley
- Tandem Diabetes receives FDA clearance for use with Android smartphones